Clinical Trials
5
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.
Phase 1
Recruiting
- Conditions
- Solid TumorsRefractory Cancer
- Interventions
- Drug: CBA-1535+Pembrolizumab
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Chiome Bioscience Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT07016997
- Locations
- 🇯🇵
Shizuoka Cancer Center, Nagaizumicho, Shizuoka, Japan
🇯🇵National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients with Advanced Solid Tumors and Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Chiome Bioscience Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06636435
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵National Cancer Center Hospital, Chuo, Tokyo, Japan
News
No news found